UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000007151
Receipt number R000008421
Scientific Title Clinical investigation for lumbar degenerative disease with osteoporosis to elucidate the effect of bony fusion in the presence or absence of PTH
Date of disclosure of the study information 2012/01/30
Last modified on 2017/04/11 15:42:12

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Clinical investigation for lumbar degenerative disease with osteoporosis to elucidate the effect of bony fusion in the presence or absence of PTH

Acronym

Clinical investigation of PTH for implanted spinal surgery

Scientific Title

Clinical investigation for lumbar degenerative disease with osteoporosis to elucidate the effect of bony fusion in the presence or absence of PTH

Scientific Title:Acronym

Clinical investigation of PTH for implanted spinal surgery

Region

Japan


Condition

Condition

Osteoporosis with vertebral degeneration

Classification by specialty

Orthopedics

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To elucidate the effect of PTH to induce bony fusion, decrease pseudoarthrodesis or loosening of pedicle screws, and improve clinical symptoms for aged lumbar degenerative diseases.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2

Pragmatic

Developmental phase



Assessment

Primary outcomes

Fusion rate
Intervertebral disc narrowing and instability
Appearance rate of screw loosening

Key secondary outcomes

ADL and QOL
femoral bone mineral density
bone metabolic markers


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -but assessor(s) are blinded

Control

No treatment

Stratification

NO

Dynamic allocation

NO

Institution consideration

Institution is considered as a block.

Blocking

YES

Concealment

Central registration


Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Teriparatide treatment (6 months)

Interventions/Control_2

Non-treatment (6 months)

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

50 years-old <=

Age-upper limit


Not applicable

Gender

Female

Key inclusion criteria

1. Patients with lumbar degenerative disease and surgical indication for one level PLIF or TLIF.
2. Patients limited only female and more than 50 years-old.
3. Patients less than 80% YAM of any site examined by DXA, or patients with fragility fracture at any site, for example on lumbar spine, femur, radius or humerus.

Key exclusion criteria

1) The following patients considered to be at high risk of developing osteosarcoma (bone sarcoma).
-Patients with Paget's disease of the bone.
-Patients with high alkaline phosphatase of unknown cause.
-Patients with history of radiotherapy likely to have affected the bone.
2) Patients with hypercalcaemia.
3) Patients with primary malignant osteosarcoma or metastatic bone tumor.
4) Patients with metabolic bone diseases except osteoporosis (hyperparathyroidism etc.).
5) Patients with a history of hypersensitivity to the constituents of TERIBONE for Subcutaneous Injection or other teriparatide formulations.
6) Women who are pregnant or may become pregnant.

Target sample size

60


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Hirotaka Haro, M.D., Ph.D

Organization

University of Yamanashi

Division name

Department of Orthopaedic Surgery

Zip code


Address

1110 Shimokato, Chuo, Yamanashi 409-3898, Japan

TEL

055-273-6768

Email

haro@yamanashi.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Yukihiro Isogai

Organization

ASAHI KASEI PHARMA Co.

Division name

Medical Affairs Dept.

Zip code


Address

1-105 Kanda Jinbocho, Chiyoda-ku, Tokyo 101-8101, Japan

TEL

03-3296-3647

Homepage URL


Email

isogai.yb@om.asahi-kasei.co.jp


Sponsor or person

Institute

University of Yamanashi, Department of Orthopaedic Surgery

Institute

Department

Personal name



Funding Source

Organization

ASAHI KASEI PHARMA Co.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor

Shinshu University, School of Medicine, Department of Orthopaedic Surgery
Hamamatsu University School of Medicine, Department of Orthopaedic Surgery

Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2012 Year 01 Month 30 Day


Related information

URL releasing protocol


Publication of results

Published


Result

URL related to results and publications

http://journals.lww.com/jbjsjournal/subjects/Spine/Fulltext/2017/03010/Role_of_Weekly_Teriparatide_A

Number of participants that the trial has enrolled


Results

Results: Seventy-five patients were randomized to treatment, and 66 patients completed treatment. At 4 months postoperatively, bone fusion in the 2 center CT slices was significantly higher in the teriparatide arm compared with the control arm in the age-adjusted modified intention-to-treat analysis and was significantly higher at 6 months in the per-protocol analysis. Radiographic examinations showed no disc-space narrowing and no intervertebral disc instability. JOABPEQ and ODI results were improved postoperatively in both treatment arms.

Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2012 Year 01 Month 30 Day

Date of IRB


Anticipated trial start date

2012 Year 01 Month 30 Day

Last follow-up date

2014 Year 07 Month 01 Day

Date of closure to data entry

2015 Year 07 Month 31 Day

Date trial data considered complete

2015 Year 08 Month 31 Day

Date analysis concluded

2015 Year 12 Month 31 Day


Other

Other related information



Management information

Registered date

2012 Year 01 Month 27 Day

Last modified on

2017 Year 04 Month 11 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000008421


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name